Cancer Institute A national cancer institute
designated cancer center

George Triadafilopoulos

Publication Details

  • Proton pump inhibitors and their drug interactions: an evidence-based approach EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY Gerson, L. B., Triadafilopoulos, G. 2001; 13 (5): 611-616


    The proton pump inhibitors (PPIs) are the most effective antisecretory agents used to treat acid-related disorders. As such, they are frequently prescribed for patients who are concurrently using other medications. PPIs may interact with other drugs through numerous mechanisms. The most important include competitive inhibition of hepatic cytochrome P (CYP) 450 enzymes involved in drug metabolism, and alteration of the absorption of other drugs via changes in gastric pH levels. Poor metabolizers, who lack CYP2C19, may be particularly predisposed to drug interactions. Although the potential for drug interactions is high, few clinically significant interactions have been reported for the PPIs. Nevertheless, caution is indicated when certain drugs are co-prescribed with these agents. The incidence of clinically significant drug interactions increases proportionately with the number of drugs taken and with the age of the patient. The drug interaction with the greatest clinical importance is the reduction in benzodiazepine clearance by omeprazole.

    View details for Web of Science ID 000168943100025

    View details for PubMedID 11396546

Stanford Medicine Resources:

Footer Links: